AmoebaCompany research
Click on headlines below to download research
Scaling up for commercialisation
Amoeba | 22/05/2023
Following on from the press release in March that provided preliminary data on the FY22 results, Amoéba has published its FY22 universal registration…
Building on an exceptional year
Amoeba | 03/04/2023
FY22 was an exceptional year for Amoéba in which it secured regulatory approval in the United States and a recommendation for approval in the European…
Fighting pathogens, respecting nature
Amoeba | 13/03/2023
During 2022 Amoéba secured regulatory approval in the United States and a recommendation for approval in the European Union for the active substance…